Beyond Alzheimer’s disease, glutaminyl cyclase (QC) has emerged as a therapeutic target in a range of conditions characterized by inflammation and protein aggregation, due to its role in the pyroglutamation and maturation of several pE-modified chemokines and peptide hormones [55]. This evidence concerns the gene QPCT and early-onset autosomal dominant Alzheimer disease.